文献速递肾小球疾病

将病理组学纳入IgA肾病风险预测

Incorporating Pathomics Into IgAN Risk Prediction.
PubMed 文献 · Kidney Int Rep · 2026-07-22

本研究基于欧洲多中心555例成人IgA肾病活检队列(VALIGA),评估25个可解释病理组学预测因子在传统MEST-C评分和IIgAN-PT基础上的增量预后价值。结果显示病理组学单独使用时C统计量略优于MEST-C(Δ 0.04),但校正临床预测因子后略差(Δ -0.034);联合传统组织学对IIgAN-PT有轻微改善(Δ 0.024)。病理组学与MEST-C非劣效,支持更标准化的风险分层。

要点

  • 病理组学单独预测IgA肾病预后略优于MEST-C评分。
  • 校正临床因素后病理组学略逊于MEST-C,二者非劣效。
  • 病理组学联合传统组织学对IIgAN-PT仅有轻微改善。

核心结论

  • 病理组学衍生的数字组织生物标志物提供额外信息层,且非劣效于MEST-C评分,支持更标准化、稳健和可重复的IgA肾病风险分层。

研究设计与样本

  • 多中心欧洲队列分析555例活检证实的成人IgA肾病(VALIGA),包含集中组织病理学评估。
  • 评估25个临床可解释的候选病理组学预测因子,在两种临床相关设置下比较病理组学与传统组织学和扩展IIgAN-PT。
  • 模型性能通过整体拟合、区分度、重分类和校准评估。

主要发现

  • 病理组学单独使用时C统计量略优于MEST-C评分(Δ C-statistic 0.04,95%CI 0.03-0.06)。
  • 校正临床预测因子后病理组学略差于MEST-C(Δ C-statistic -0.034,95%CI -0.042至-0.027)。
  • 病理组学联合传统组织学对当前IIgAN-PT(不含种族)仅有轻微改善(Δ C-statistic 0.024,95%CI 0.019-0.028)。
  • 病理组学变量捕获慢性形态学改变,包括肾小球变形、肾小管萎缩和动脉管腔狭窄。
  • 两种模型对患者临床风险分组的分层一致。

关键数值与推荐

  • 病理组学单独vs MEST-C:Δ C-statistic 0.04(95%CI 0.03-0.06)。
  • 校正临床预测因子后病理组学vs MEST-C:Δ C-statistic -0.034(95%CI -0.042至-0.027)。
  • 联合病理组学与传统组织学vs IIgAN-PT(不含种族):Δ C-statistic 0.024(95%CI 0.019-0.028)。

临床怎么用

  • 病理组学可作为MEST-C的补充工具,提供标准化、可重复的定量形态学信息。
  • 病理组学联合传统组织学对IIgAN-PT的改善幅度较小,需权衡增量价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide, with heterogeneous progression rates. The International IgAN Prediction Tool (IIgAN-PT) enables individualized risk prediction using clinical characteristics and histopathological scoring. However, traditional histopathological scoring is semiquantitative and prone to interobserver variability. Deep learning-based, automated quantification of digitized histopathology enables the extraction of quantitative morphological biomarkers (pathomics). Here, we evaluated the added prognostic value of pathomics over traditional histopathology and its potential integration into the IIgAN-PT. METHODS: We analyzed a multicenter European cohort of 555 adults with biopsy-proven IgAN (VALIGA), including centralized histopathology assessment. We assessed the potential of 25 clinically interpretable candidate pathomics predictors across 2 clinically relevant settings by (i) comparing pathomics with traditional histopathology (MEST-C [mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S), tubular atrophy and/or interstitial fibrosis (T) and crescents (C)]) and (ii) extending the IIgAN-PT with pathomics. Model performance was evaluated by overall fit, discrimination, reclassification, and calibration. RESULTS: In a direct comparison, pathomics slightly outperformed the MEST-C score when used alone (Δ C-statistic 0.04 (95% confidence interval [CI]: 0.03-0.06)) but was marginally worse after adjusting for clinical predictors (Δ C-statistic -0.034 [95% CI: -0.042 to -0.027]). Patient stratification into clinical risk groups was consistent between models. Combining pathomics and traditional histopathology led to minor improvements over the current IIgAN-PT (without ethnicity, Δ C-statistic 0.024 [95% CI: 0.019-0.028]). Pathomics variables captured chronic morphological changes including glomerular deformation, tubular shrinkage, and arterial luminal narrowing. CONCLUSION: Our findings indicate that pathomics-derived digital tissue biomarkers provide an additional layer of information and are noninferior to MEST-C, supporting more standardized, robust, and reproducible risk stratification in IgAN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Hölscher DL, Barbour SJ, Coppo R, et al. Incorporating Pathomics Into IgAN Risk Prediction. Kidney Int Rep. 2026. PMID: 42661948. doi:10.1016/j.ekir.2026.106708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。